Drug Trial Radar · NCT05209308
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
Last checked: Nov 19, 2026Latest source record: Mar 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Nov 22, 2022
Primary completion
Mar 15, 2023
Study completion Mar 15, 2023
Sponsor
- Lead sponsor
- MEI Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Kyowa Kirin, Inc.
- First posted
- Jan 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 study of Zandelisib with Venetoclax (VEN) and Rituximab (R) in subjects with Relapsed/Refractory CLL.
Conditions
- CLL
Interventions
ZandelisibDrug
Zandelisib taken orally for 7 days of each 28 day cycle
RituximabDrug
Rituximab IV for 6 cycles
VenetoclaxDrug
Orally - Ramp up weeks 1-5
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the uMRD rate in PB and BM by flow cytometryTime frame: 2 year
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Dana Farber Cancer Institute
Boston, Massachusetts
Stony Brook University
Stony Brook, New York
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma
Medical Oncology Associates, PS (dba Summit Cancer Centers)
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.